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Abstract 
Background 
Age-related macular degeneration (AMD) is the leading cause of blindness among older 
adults in the developed world. The only treatments currently available, such as ranibizumab 
injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the 
condition. Hypoxia has been implicated as one of the primary causes of AMD, and is most 
acute at night when the retina is most metabolically active. By increasing light levels at night, 
the metabolic requirements of the retina and hence the hypoxia will be considerably reduced. 
This trial seeks to determine whether wearing a light mask that emits a dim, green light 
during the night can prevent the progression of early AMD. 
Methods/design 
ALight is a Phase I/IIa, multicentre, randomized controlled trial. Sixty participants (55 to 88 
years old) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye will 
be recruited from nAMD clinics. They will be randomized (in the ratio 1:1), either to receive 
the intervention or to be in the untreated control group, stratified according to risk of disease 
progression. An additional 40 participants with healthy retinal appearance, or early AMD 
only, will be recruited for a baseline cross-sectional analysis. The intervention is an eye mask 
that emits a dim green light to illuminate the retina through closed eyelids at night. This is 
designed to reduce the metabolic activity of the retina, thereby reducing the potential risk of 
hypoxia. Participants will wear the mask every night for 12 months. Ophthalmologists 
carrying out monthly assessments will be masked to the treatment group, but participants will 
be aware of their treatment group. The primary outcome measure is the proportion of people 
who show disease progression during the trial period in the eye with early AMD. A co-
primary outcome measure is the rate of retinal adaptation. As this is a trial of a CE-marked 
device for an off-label indication, a further main aim of this trial is to assess safety of the 
mask in the cohort of participants with AMD. 
Trial registration 
International Standard Randomised Controlled Trials Register: ISRCTN82148651 
Keywords 
age-related macular degeneration, biomarker, hypoxia, light mask, randomized controlled 
trial 
Background 
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed 
world [1] and is responsible for more than 50% of visual impairment registrations in the UK 
[2]. For the majority of people with AMD, there is no treatment. The remaining 10 to 15% of 
people with the advanced, neovascular, form of the disease (nAMD) are mainly treated with 
intra-ocular injections of ranibizumab, an anti-vascular endothelial growth factor agent [3]. 
Follow-up treatment for these patients is long-term and places a significant burden on the UK 
National Health Service. Indeed, advanced AMD currently costs the British economy £1.2 
billion to £3.7 billion per annum [2,4,5]. Furthermore, the disease is associated with 
depression, falls and social isolation [6,7]. Given this significant socioeconomic problem, 
there is a great need to evaluate potential therapeutic interventions that attempt to treat the 
disease at an early stage, to prevent vision loss from occurring. 
Age-related macular degeneration is characterized by the dysfunction and death of 
photoreceptors in the central retina. There is an increasing amount of evidence to suggest that 
hypoxia plays a major role in its pathogenesis [8,9]. This has been attributed to various 
factors, including a disruption of choroidal circulation [10-13], and thickening and deposition 
of drusen at Bruch’s membrane [9,14]. The latter increases the distance over which oxygen 
must travel to reach the retinal pigment epithelium from the choroidal circulation. Disease-
related changes to Bruch’s membrane also impair the diffusion of nutrients and growth 
factors, which consequently exacerbates choroidal perfusion abnormalities, promoting further 
hypoxia [8,15]. 
Even in the healthy retina, intraretinal oxygen profiles obtained from animals show that the 
oxygen tension at the proximal side of the photoreceptor inner segments is close to zero in 
darkness [16,17]. This is attributable to the metabolic demand of the ‘dark current’ in the 
retina’s approximately 120 million rods [18]. When this limited supply of oxygen to the outer 
retina is further compromised by the changes to the choroidal circulation and Bruch’s 
membrane that occur in AMD, hypoxia may result. This hypoxia could be the precursor for 
increased vascular endothelial growth factor production and apoptosis [19,20]. 
The fragile balance between metabolic demand and oxygenation is exemplified functionally 
by the adverse effects of hypoxia on colour vision [21-23], dark adaptation [24,25], mesopic 
sensitivity [26] and the electroretinogram [12,27-29]. To date, there is no direct evidence of 
the effect of hypoxia on visual function in AMD. However, there is evidence that scotopic 
threshold elevation and prolonged electroretinogram implicit times are associated with areas 
of reduced choroidal blood flow in AMD [30,31] and pilot data from our laboratory show a 
transient reduction in scotopic thresholds in an individual with early AMD whilst inhaling 
oxygen. 
Environmental manipulation of light levels can substantially reduce the metabolic demands 
on the outer retina, thereby reducing the need for oxygen, and potentially providing an 
intervention that would delay the progression of conditions with a hypoxic aetiology [32]. A 
pilot study by Arden et al. [33] found no adverse effects from the provision of low-level night 
lighting over the course of 12 months in individuals with diabetic retinopathy [33]. 
Furthermore, a recent clinical trial in patients with diabetic macular oedema who wore a low-
level light mask during the night for 6 months reported a reduction in oedema and an 
improvement in functional measures, which was attributed to the obviation of night-time 
hypoxia [34]. In this trial, we will be using the same intervention (low-level light therapy) to 
determine its ability to prevent the development of AMD. 
Methods/design 
Trial objectives 
The primary aim of this study is to collect preliminary Phase I/IIa proof-of-concept trial data 
from people with early AMD in one eye and advanced nAMD in the fellow eye, recruited 
from a hospital nAMD clinic, in order to assess the impact of low-level night-time light 
therapy, compared with no intervention, on disease progression in the eye with early AMD. A 
further main aim of this trial is to assess safety of the mask in the cohort of participants with 
AMD. 
The secondary aims of the study are to: 
1. Establish the effect of low-level night-time light therapy, compared with no-treatment 
control, on secondary outcome measures, including: change in drusen volume from 
baseline in the eye with early AMD; ranibizumab retreatment rates in the fellow eye 
with nAMD; progression of early AMD on the basis of change in functional outcome 
measures; change in health-related quality of life (assessed using the EuroQol EQ-5D 
instrument); change in self-reported visual function assessed using the 48-item 
Veterans Affairs Low-Vision Visual Functioning Questionnaire (VA LV VFQ-48). 
2. Establish the acceptability of low-level night-time light therapy in people with AMD 
by monthly qualitative interviews. 
3. Determine the effect of low-level night-time light therapy on sleep patterns by 
conducting the Pittsburgh Sleep Quality Index (PSQI) questionnaire every month with 
both intervention arms by interview with the study investigator. 
4. Establish the relationship between baseline functional biomarker outcomes and the 
severity of AMD (assessed using the simplified Age-Related Eye Disease Scale 
(AREDS) and initial drusen volume). 
5. Evaluate the ability of all clinical tests to act as prognostic biomarkers for AMD 
progression. 
6. Evaluate the ability of all clinical tests to act as predictive biomarkers for low-level 
night-time light therapy in people with AMD. 
7. Compare the sensitivity of all clinical tests to disease progression over 12 months. 
Study design and setting 
ALight is a Phase I/IIa prospective proof-of-concept randomized controlled trial, consisting 
of two parallel groups. Trial recruitment and data collection will take place at the Medical 
Retina Clinic, Bristol Eye Hospital. Additional cross-sectional data will be collected from 
people with healthy eyes, or only early signs of AMD, at the Cardiff University School of 
Optometry and Vision Sciences. 
Eligibility criteria 
Inclusion criteria 
• Between the ages of 55 and 88 years. 
• Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity of 0.3 
logMAR (Snellen 20/40 or 6/12) or better in the test eye. 
• Early AMD in the study eye. 
• nAMD in the fellow eye, within a month of the third Ranibizumab injection (trial 
only). 
• Willing to adhere to allocated treatment for duration of trial. 
Exclusion criteria 
• Ocular pathology other than macular disease. 
• Significant systemic disease or medication known to affect visual function. 
• Systemic disease that would compromise participation in a 1-year study (trial only). 
• Insufficient English language comprehension. 
• Cognitive impairment as determined using an abridged Mini Mental State 
Examination [7]. 
• Oxygen mask worn at night. 
Suspension criteria for the trial 
• Participant wishes to discontinue the study. 
• Serious adverse events (for example, conversion to nAMD in the test eye) or 
unexpected changes in clinical status. 
Interventions 
Participants allocated to the treatment group will be given a 12-weekly disposable light mask 
(Polyphotonix Medical, UK) that presents organic light-emitting diode illumination (peak 
output 502 nm) to both eyes, to be used overnight for 12 weeks. Light masks will be replaced 
every 12 weeks at the participant’s routine appointment at the nAMD clinic so that the total 
duration of mask usage is 12 months. 
The mask provides a luminance of 75 photopic cd/m2. When adjusted for the spectral 
sensitivity of rod photoreceptors, this equates to 186 scotopic cd/m2 [35]. Light transmission 
by the human eyelid has been found to range between 0.3% and 2% for light in the region of 
500 to 505 nm [36-38]. Under these conditions, the pupil diameter in people in the age group 
60 to 85 years is approximately 4 mm [39]. This will result in a retinal illuminance in the 
order of 23 scotopic Td (assuming an eyelid transmission of 1%). 
The masks will be pre-programmed to function only between specific hours, that is, 8 pm to 8 
am, to prevent misuse. Outside of these hours, they will not illuminate if worn. The mask is 
activated when a touch sensor on the device is gently covered with a finger for 3 seconds. It 
will deactivate if not worn continuously for the first 15 minutes, and after that, the light will 
remain on for the remainder of the 8-hour period. 
Treatment acceptability will be evaluated during a monthly interview with the study 
investigator. Compliance data will be obtained at the monthly visit from the treatment group 
both (i) through evaluation of a diary of mask usage, and (ii) objectively through data 
collected on a chip in the mask itself (based on a sensor which logs when the mask is in 
contact with the face). This provides precise data on the hours the mask is worn each night by 
each participant. As each mask is programmed with the unique participant identification 
code, compliance data stored on-chip will be non-identifiable except via the password-
protected electronic database. 
The current management of patients with early AMD involves advising on lifestyle factors, 
such as stopping smoking and improving diet. The only other intervention that is based on 
evidence from a robust randomized controlled trial is the provision of a nutritional 
supplement consisting of high-dose antioxidants plus zinc. This AREDS group formula 
(vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg and zinc, 80 mg) has been 
shown to reduce risk of progression from early to advanced AMD by around 20% over 5 
years in people with specific features of AMD [40]. However, a recent systematic review by 
the Cochrane Collaboration indicated that there may be an increased risk of mortality in 
individuals taking vitamin E and beta carotene supplementation [41]. As this is a recently 
published document, its advice is not reflected in the current guidelines for the management 
of AMD. For this reason, the low-level light therapy will be compared with a no-treatment 
control, rather than with the AREDS group formula as the best current intervention. 
Participants in both groups will receive routine ophthalmological care for the eye with nAMD 
(that is, ranibizumab injections). If the eye with early AMD converts to nAMD, the 
participant will proceed to ranibizumab treatment for this eye also, and will be withdrawn 
from the study. 
Outcome measures 
This study includes two co-primary outcome measures, reflecting structural status and 
functional status. 
• The proportion of people who show ‘disease progression’ in the eye with early AMD 
during the 12 months of the study based on an increase in drusen volume beyond test-
retest repeatability limits or a progression to advanced AMD. Software available for 
the Cirrus optical coherence tomography (OCT) system allows automated assessment 
of drusen volume. Irrespective of initial drusen volume, approximately 50% of people 
with AMD show a significant increase in drusen volume over the 12-month study 
period, that is, beyond test-retest 95% confidence intervals [42]. Conversion to 
advanced disease will also be considered to be an indicator of disease progression in 
this analysis. Data from a trial on a similar group indicates that about 10% of people 
meeting our inclusion criteria will develop advanced AMD within 12 months [43]. 
Hence, 60% of participants might be expected to show progression based on increased 
drusen volume or progression to late AMD. The development of advanced AMD will 
be determined on the basis of ophthalmologist diagnosis at the monthly follow-up 
appointments at the nAMD clinic. 
• The rate of retinal adaptation (time taken for photoreceptors to recover their 
sensitivity after being exposed to a bright adapting light). 
Secondary outcome measures include: the change in drusen volume over the 12 month 
follow-up period; the number of ranibizumab retreatments required during the year in the 
fellow eye with nAMD (assessed through review of medical records at the end of 12 months); 
changes in visual function including chromatic thresholds, visual acuity and psychophysical 
14 Hz flicker thresholds; self-report outcome measures, including health-related quality of 
life (EQ-5D) and visual function (VFQ-48) [44]; a sleep quality questionnaire (PSQI) and a 
semistructured interview (conducted monthly by interview) to determine intervention 
acceptability. 
To obtain detailed information about the time course of any therapeutic action, the primary 
and the first of the secondary outcome measures (based on drusen volume) will be assessed at 
baseline and then at monthly intervals (using OCT images obtained at the regular nAMD 
clinic follow-up appointments). 
Participant timeline 
The study flow diagram (Figure 1) outlines the appointment schedule. In brief, potential 
participants are identified at their first visit to the nAMD clinic. At the second visit (1 month 
later), informed consent will be obtained, and screening tests and baseline questionnaires will 
be carried out. At the third monthly visit, baseline functional tests will be carried out, and 
participants will be randomly assigned to either the treatment or intervention group. 
Participants in both intervention groups will attend a short, monthly follow-up appointment 
following their routine appointment at the nAMD clinic throughout the year. Final outcome 
data will be collected from control and intervention groups at a 12-month follow-up 
appointment, scheduled to follow a regular visit to the nAMD clinic. 
Figure 1 Study flow diagram showing participant timeline. 
Participants in the cross-sectional baseline study will attend Cardiff University or the Bristol 
Eye Hospital for one visit only. 
Recruitment 
Sixty participants will be recruited to the trial. Ophthalmologists will identify potential trial 
participants who are attending for their first appointment at the nAMD clinic at Bristol Eye 
Hospital, and will provide them with an information sheet and ask for their permission to be 
contacted by the study investigators. The potential participants will be contacted at least 2 
days after their receipt of the information sheet, and invited to meet the study investigator at 
their next visit to the nAMD clinic (approximately 1 month later) to discuss the trial, provide 
consent if they choose to participate, and carry out some basic screening tests. Participants 
will be informed after this screening visit whether they are eligible to take part in the study. 
Owing to the low number of patients required to participate in the study it is planned for the 
trial and data collection to take place principally at a single NHS centre, that is, the Bristol 
Eye Hospital. If needed, additional participants will be recruited from supplementary 
recruitment centres to ensure that targets are met. 
Forty control participants and participants with grade 1 AMD (AREDS simplified scale [45]) 
for the baseline cross-sectional analysis will be recruited by local optometrists in Bristol and 
Cardiff, from a database of elderly volunteers, from the Bristol Eye Hospital, from the list of 
research volunteers at the Cardiff University Eye Clinic and from staff and students of 
Cardiff University. 
Randomization 
Participants will be stratified according to risk of AMD progression (using the AREDS 
simplified scale [45]), and randomly allocated to receive either the light mask or no 
intervention in a 1:1 ratio using computer-generated random permuted blocks (both groups 
will continue to receive ranibizumab injections as required for the fellow eye). The study 
investigator will be provided with three piles of envelopes by the chief investigator, in order 
to randomize the participant to either the intervention or control arm of the study. Each pile 
relates to a different stratum of randomization, that is, grade 2, 3 or 4 of AMD, according to 
the AREDS simplified scale. The envelopes in each pile will be numbered, and will contain 
the randomization allocation for each participant. 
Masking 
It is not appropriate in this study to use a sham treatment, since a non-illuminated mask may 
have a physiological effect on the retina and patients would be aware that they weren’t 
perceiving light and so would be unmasked to their intervention group. The study investigator 
who collects the outcome data will also be providing the masks and instructions on its usage 
and, hence, will not be masked to the intervention group. However, the potential for 
experimenter bias is limited, as the primary outcome measure, disease progression, is an 
objective measurement carried out by automated computer software. The ophthalmologists 
who are seeing the participants for their regular ranibizumab injections will be masked, which 
will prevent any bias in their retreatment decisions for the fellow eye. 
Data collection methods 
Screening visit 
Following a discussion of the study, and the obtaining of informed consent, the study 
investigator will question the participant regarding ocular and medical history. Retinal 
photographs will be taken if they have not already been acquired, and repeated if image 
quality is insufficient to allow evaluation. The OCT and fundus photographs will be assessed 
to check for eligibility. The Van Herick angle of drainage will be measured, media clarity 
will be assessed for each eye and the lens graded according to the Lens Opacities 
Classification System III grading scale [46]. Visual acuity will be assessed in each eye using 
the ETDRS chart, following a brief refraction, if necessary. An abridged version of the Mini 
Mental State Examination will be used to assess for cognitive impairment (5 min; [7]). 
Those still deemed eligible for inclusion in the study will also complete several 
questionnaires, through verbal interview with the investigator: visual function (VA LV VFQ-
48) [44]; health-related quality of life (EQ-5D); sleep quality (PSQI) [47]; smoking history 
(pack years); vitamin supplementation; ethnic origin. 
Baseline assessment 
Optical coherence tomography images and fundus photographs obtained during the 
participant’s routine visit to the ranibizumab clinic will be obtained and analyzed to assess 
drusen volume and AMD grade, according to the AREDS simplified scale [45]. If the images 
are of insufficient quality, additional images will be captured. 
The ETDRS visual acuity will be assessed in each eye. Chromatic thresholds will be 
measured for the eye with early AMD using the Colour Assessment and Diagnosis test [48] 
(City Occupational Ltd). Contrast thresholds to a 14 Hz flickering stimulus will be measured 
for the eye with early AMD using the procedure outlined by Dimitrov et al. [49]. The rate of 
parafoveal cone dark adaptation will be determined for the eye with early AMD using a 
psychophysical procedure described previously [50]. Thresholds will be determined using a 
psychophysical method, based on a ‘3 down, 1 up’ staircase paradigm [50]. An array of white 
light-emitting diodes behind a diffusing filter will be used to light-adapt photoreceptors in the 
central 43.6° of the test eye (the output of the white light-emitting diodes will be modified by 
a Lee filter, HT015, to provide a retinal illuminance of 5.20 log phot Td.s−1, providing a 
bleach of 85% cone photopigment and 74% rhodopsin). All light levels fall within the safety 
guidelines set out in British Standard BS EN 15004-2 (2007) [51]. There will be an initial 
training phase, of around 5 minutes, then the adapting light will be presented, and finally 
recovery of visual thresholds will be monitored for 25 minutes after exposure to the adapting 
light. 
Those individuals who are assigned to the treatment group will then be given a light mask, 
and provided with written and oral instructions on its use. There will also be a reprise of the 
key information provided in the participant information letter about follow-up appointments. 
Participants will be given written copies to take home of the PSQI questionnaire that will be 
used in the monthly interview. 
Monthly assessment 
The investigator will access the OCT images and medical records of all participants after they 
have attended the ranibizumab clinic for each monthly follow-up appointment. This will 
allow measurement of drusen volume on a monthly basis, which will allow the final analysis 
to include an assessment of the time course of any therapeutic action. Additionally, reviewing 
medical records will facilitate monitoring of the conversion rate to advanced AMD in the 
control and intervention groups in the eye with early AMD at baseline, and of ranibizumab 
retreatment rates in the eye with nAMD, for adverse event reporting purposes. 
Participants in both intervention groups will attend a short, monthly follow-up appointment 
following their routine ranibizumab clinic appointment, during which both groups will 
complete the PSQI sleep quality questionnaire. In addition, the treatment group will bring 
their mask along to each monthly visit to allow objective compliance data (nightly hours of 
use) to be exported from the device, retraining in mask use if required, functionality of the 
mask to be checked, masks to be replaced every 12 weeks, and a semistructured interview to 
be carried out to determine the acceptability of the intervention. These data will be used to 
address secondary objectives 2 and 3. 
Final (12-month) visit 
This visit will be the same as the baseline visit with the addition of a final semistructured 
interview assessing the acceptability of the intervention, and the questionnaires (PSQI, VA 
LV VFQ-48, Euroqol). 
Baseline cross-sectional study 
The 40 participants recruited only to the cross-sectional part of the study will undergo the 
tests outlined in the baseline assessment visit of the trial. 
Statistical methods 
It should be noted that, as a Phase I/IIa proof-of-concept study, this research is designed to 
assess the acceptability of this therapy for the participants, and to provide preliminary data to 
support a larger Phase III randomized controlled trial in the future, and so is not powered to 
detect small effect sizes. To maximize retention, all follow-up visits will be timed to coincide 
with scheduled appointments at the nAMD clinic. We will aim to recruit 60 people, which, 
allowing for 15% dropout through the year, should leave a final cohort of 51. This will be 
sufficient to detect a 50% reduction in people showing progression at a probability level of 
0.2, with a power of 80%, and a change in the time constant of cone adaptation of 1 minute to 
be detected at a probability level of 0.05, with a power of 80%. The additional 40 participants 
enrolled into the cross-sectional part of the study will allow a total cohort of n = 100 to 
address secondary aim 4. 
Analysis will be carried out on an intention-to-treat basis. There will be no interim analysis, 
but conversions to nAMD in the eye with early AMD at baseline, and ranibizumab 
retreatments for the fellow eye, will be recorded at each participant visit to the nAMD clinic 
for safety monitoring purposes. 
This trial will primarily be concerned with providing information about the safety of the 
device in the treatment of AMD, and the magnitude of any treatment effect. On this basis, 
descriptive statistics will be carried out to summarize the demographic characteristics of the 
two groups, as well as the proportion of individuals showing disease progression in each 
group, the magnitude of changes in secondary outcome measures, including drusen volume, 
measures of visual function, and the self-report tests, and the fellow eye retreatment rates. 
The primary outcome measure will be the proportion of patients demonstrating disease 
progression at 12 months. Comparisons will be performed using stratified Mantel-Haenszel 
tests and presented as forest plots. 
Formal statistical analysis will also include linear regression analysis to investigate changes 
in drusen volume controlling for intervention arm, baseline drusen volume and patient 
characteristics (such as age, vitamin supplement intake and history of smoking). Analysis of 
covariance (ANCOVA) will be carried out to compare the change in secondary outcome 
measures (for example, drusen volume, functional tests, self-report measures) and the 
ranibizumab retreatment rates over 12 months between the two intervention arms, controlling 
for the characteristics listed previously. Note that all analysis except for the ranibizumab 
retreatment rate pertains to the eye with early AMD. This will address secondary aim 1. To 
meet our fourth secondary aim, which is to establish the relationship between baseline 
functional biomarker outcomes and the severity of AMD, we will carry out a one-way 
analysis of variance (ANOVA) to compare the mean results at baseline between participants 
with grades of AMD in each group on the AREDS simplified scale. This analysis will take 
place when the baseline data collection is complete. To assess the ability of the clinical tests 
to act as prognostic and predictive biomarkers, receiver operating characteristics curves will 
be constructed to plot the sensitivity and specificity of the baseline measures in predicting 
outcomes within the control and intervention arms, respectively. This will address secondary 
aims 5 and 6. When the trial is completed, linear regression analysis will be used to determine 
how well the change in the functional measures relate to the change in our primary outcome 
measure (drusen volume), which is a validated biomarker for disease progression. This will 
address the seventh secondary aim. 
Trial management 
The chief investigator has ultimate responsibility for the trial management, assisted by the 
trial management group. Any important protocol modifications will be communicated to all 
relevant parties (investigators, research ethics committee, NIHR CRN Portfolio, trial registry, 
journals, NHS Research and Development, device manufacturer, funding body) by the chief 
investigator. 
A trial steering committee has been established, which will also act as a data monitoring 
committee. In addition to annual meetings, the committee will be issued with information 
about any adverse events throughout the course of the study, so that they can decide whether 
it is appropriate for the study to be terminated. A 3-monthly newsletter will be issued to all 
investigators and the steering committee, updating on recruitment and other issues, 
throughout the trial. 
Safety monitoring 
All adverse events (AEs) and serious adverse events (SAEs) will be recorded. The chief 
investigator (AB) will be provided with an update of AEs every month and all SAEs within 
two working days. This trial does not involve a medicinal product or life-threatening 
procedure. Hence, the risk of a SAE is low. However, one potential SAE is an increased rate 
of progression to nAMD in the eye with early AMD at baseline. Although this is at odds with 
the literature, it is not an impossible outcome. Another potential SAE would be an increased 
rate of recurrence of nAMD in the fellow eye (resulting in increased ranibizumab retreatment 
rates). Conversion to nAMD and Ranibizumab retreatment requirement in the fellow eye will 
be determined by ophthalmologists at the monthly ranibizumab clinic, and recorded by the 
study investigator through assessment of medical records after each monthly ranibizumab 
appointment. 
Wong et al. [52] carried out a meta-analysis of studies, which had looked at the progression 
to choroidal neovascularization in the fellow eye when free of advanced disease at study 
inception. They reported that the cumulative 1-year incidence of nAMD in the 426 patients 
enrolled in the five studies that evaluated this outcome was 12.2% (confidence interval, 1.7% 
to 30.6%). Therefore, we have placed an upper limit on the number of people expected to 
convert to nAMD per month of n × (30.6% / 12 months), where n is the number of people in 
the trial who are using the light therapy light mask. 
The chief investigator will assess the nature of the AEs and SAEs for seriousness, causality 
and expectedness. Following the initial report, follow-up data may be requested by the chief 
investigator. Where the SAE is both related and unexpected, the chief investigator will notify 
the Trial Steering Committee, the trial sponsor, the National Research Ethics Service North 
West, and the device manufacturer, who will notify the Medicines and Healthcare Regulatory 
Agency within 15 days of receiving notification of the SAE. 
Data management 
Any trial data will be recorded on spreadsheets using the numerical identifier for each patient. 
These data will be non-identifiable. All paper records will also use the unique numerical 
identifier, which will be non-identifiable. The only identifiable personal data will be the 
paper and electronic copies of the patient database. The paper copy will not be transferred 
between Cardiff University and the Bristol Eye Hospital, and will be kept in a locked filing 
cabinet at all times. The electronic database will be stored on a secure Cardiff University 
computer drive, which is accessible from Bristol and Cardiff via a password-protected 
connection. The study database will be checked for integrity every month by the chief 
investigator. At the end of the trial, the data will belong to Cardiff University. At this time, 
Polyphotonix Medical Ltd (the manufacturer) will have access to the results. Anonymized 
data will be available for verification at any time by the funding body, the College of 
Optometrists, on request. Neither the College of Optometrists, nor Polyphotonix Medical Ltd. 
will influence the data collection or analysis. All data will be kept for 15 years, in line with 
Cardiff University’s Research Governance Framework Regulations for clinical research. 
Dissemination 
A summary of the trial protocol is available to the public through the International Standard 
Randomised Controlled Trials Register. Any interested individuals may contact the chief 
investigator for further information. Results will be published in peer-reviewed journals and 
at International Conferences. The chief investigator has ultimate responsibility for the 
scientific content of any publications. Dissemination of results to trial participants will take 
place through a summary-of-findings newsletter sent at the end of the trial to those 
individuals who indicate a desire to receive an update. Dissemination to the wider community 
of people with AMD will take place through publication in the Macular Society’s members’ 
magazine, Digest, and through presentations at such events as the Macular Society ‘Top 
Doctors’ conference. Neither the funding body (the College of Optometrists), the light mask 
manufacturer (Polyphotonix Medical Ltd), nor the sponsor (Cardiff University) will influence 
the presentation or the publication of the research. 
Ethical considerations 
The study has been approved by the National Research Ethics Service North West, and is 
registered with the International Standard Randomised Clinical Trials Register. A notice of 
no objection has been obtained from the Medicines and Healthcare Regulatory Agency. The 
trial will be conducted in adherence with the Declaration of Helsinki and the Good Clinical 
Practice guidelines. The chief investigator and the research team will preserve the 
confidentiality of participants in accordance with the Data Protection Act 1998. 
Audits and inspections 
The trial is liable to inspection by the College of Optometrists as the funding organization. 
The study may also be liable to inspection and audit by Cardiff University under their remit 
as sponsor. 
Discussion 
In this article, we present a clinical trial protocol to evaluate the effect of low-level night-time 
light therapy in patients with early AMD. To our knowledge, this is the first randomized 
controlled trial of its kind in AMD. This study will provide the foundation for future large-
scale clinical trials. With the prediction of longer life expectancy in the future, the prevalence 
of AMD and its associated social and economic problems will continue to increase unless a 
treatment is developed that will stop its progression. 
Trial status 
This protocol aims to establish the therapeutic benefit of low-level light therapy on disease 
progression in AMD. Recruitment will begin in April 2014 and continue until February 2015. 
Data collection will take place from June 2014 to April 2016. 
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AE, adverse event; AMD, age-related macular degeneration; ANCOVA, analysis of 
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